___

[1] Mielczarek M, Zakrzewska A, Olszewski J. GJB2 sequencing in deaf and profound sensorineural hearing loss children. Otolaryngol Pol 2016; 70 (3): 21-25.

Kochhar A, Hildebrand MS, Smith RJ. Clinical aspects of hereditary hearing loss. Genet Med 2007; 9(7): 393- 408.

Putcha GV, Bejjani BA, Bableoo S, et al. A multicenter study of the frequency and distribution of GJB2 and GJB6 mutations in a large North American cohort. Genet Med 2007; 9(7) 413- 426.

Nance WE, Lim BG, Dodson KM. Importance of congenital cytomegalovirus infections as a cause for pre-lingual hearing loss. J Clin Virol 2006; 35(2): 221- 225.

McClay JE, Booth TN, Parry DA, et al. Evaluation of pediatric sensorineural hearing loss with magnetic resonance imaging. Arch Otolaryngol Head Neck Surg 2008; 134(9): 945-952.

Prezant TR, Agapian JV, Bohlman MC, et al. Mitochondrial ribosomal RNA mutation associated with both antibiotic-induced and non-syndromic deafness. Nat Genet 1993; 4(3): 289- 294.

Kimani JW, Buchman Ca, Booker JK, et al. Sensorineural Hearing Loss in a Pediatric PopulationAssociation of Congenital Cytomegalovirus Infection With Intracranial Abnormalities. Arch Otolaryngol Head Neck Surg. 2010; 136(10): 999-1004.

Leon SA, Shapiro B, Sklaroff DM, et al. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977; 37(3): 646–650. [ Kirk GD, Lesi OA, Mendy M, et al. 249(ser) TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocel- lular carcinoma, Oncogene 2005; 24(38): 5858–5867.

Mulcahy HE, Lyautey J, Lederrey C, et al. A pro- spective study of K-ras mutations in the plasma of pancreatic cancer pa- tients, Clin. Cancer Res. 1998; 4(2): 271–275.

Salbe C, Trevisiol C, Ferruzzi E, et al. Molecular detection of codon 12 K-RAS mutations in circulating DNA from serum of colorectal cancer patients, Int. J. Biol. Markers 2000; 15(4): 300–307.

Utting M, Werner W, Dahse R, et al. Microsatellite analysis of free tumor DNA in urine, serum, and plasma of patients: a minimally invasive method for the detection of bladder cancer, Clin. Cancer Res. 2002; 8(1): 35–40.

Galeazzi M, Morozzi G, Piccini M, et al. Dosage and character- ization of circulating DNA: present usage and possible applications in systemic autoimmune disorders. Autoimmun Rev 2003; 2(1): 50–5.

Steinman CR. Circulating DNA in systemic lupus erythemato- sus: Isolation and characterization. J Clin Invest 1984; 73(3): 832–41.

Steinman CR. Circulating DNA in polyarteritis nodosa and related syndromes. Arthritis Rheum 1982; 25(12): 1425–30.

Laktionov PP, Tamkovich SN, Rykova EY, et al. Extracellular circulating nucleic acids in human plasma in health and dis- ease. Nucleosides Nucleotides Nucleic Acids 2004; 23(6-7): 879 – 83.

Davis GL, Davis JS. Detection of circulating DNA by counter- immu- noelectrophoresis (CIE). Arthritis Rheum 1973; 16(1): 52–8.

Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic ac- ids as biomarkers in cancer patients. Nature Reviews Cancer 2011; 11(6): 426-37.

Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116(2): 281-297.

Yates LA, Norbury CJ, Gilbert RJ. The long and short of mi- croRNA. Cell 2013; 153(3): 516-519.

Salajegheh A, Vosgha H, Rahman AM et al. Modulatory role of miR-205 in angiogenesis and progression of thyroid can- cer. Journal of molecular endocrinology 2015; 55(3): 183-196.

Santos MCT, Tegge AN, Correa BR et al. miR‐124,‐128, and ‐137 Orchestrate Neural Differentiation by Acting on Overlapping Gene Sets Containing a Highly Connected Transcription Factor Network. Stem Cells 2016; 34(1): 220-232.

Pagarkar W, Bitner-Glindzicz M, Knight J, et al. Late postna- tal onset of hearing loss due to GJB2 mutations. Int. J. Pediatr. Otorhinolaryngol. 2006; 70 (6): 1119–1124.

Norris VW, Arnos KS, Hanks WD, et al. Does universal newborn hearing screening identify all children with GJB2 (Connexin 26) deafness? Penetrance of GJB2 deafness. Ear Hear. 2006; 27 (6): 732–741.

Hoefsloot LH, Roux AF, Bitner-Glindzicz M. EMQN DFNB1 best practice meeting. EMQN Best Practice guidelines for diagnos- tic testing of mutations causing non-syndromic hearing im- pairment at the DFNB1 locus. Eur J Hum Genet 2013; 21(11): 1325–1329.

Burke WF, Warnecke A, Schöner-Heinisch A, et al. Prevalence and audiological profiles of GJB2 mutations in a large collec- tive of hearing impaired patients. Hear Res. 2016; 333: 77–86.

Kim SY, Kim AR, Kim NK, et al. Unraveling of Enigmatic Hearing-Impaired GJB2 Single Heterozygotes by Massive Parallel Sequencing: DFNB1 or Not? Medicine (Baltimore) 2016; 95(14): e3029.

Zhou XX, Chen S, Xie L, et al. Reduced Connexin26 in the Mature Cochlea Increases Susceptibility to Noise-Induced Hearing Loss in Mice. Int J Mol Sci 2016; 17(3): 301.

Van Eyken E, Van Laer L, Fransen E, et al. The contribution of GJB2 (Connexin 26) 35delG to age-related hearing impair- ment and noise-induced hearing loss. Otol Neurotol 2007; 28(7): 970–975.

Matsushima K, Nakano A. Arimoto Y, et al. High-level hetero- plasmy for the m.7445A>G mitochondrial DNA mutation can cause progressive sensorineural hearing loss in infancy. Int J Pediatr Otorhinolaryngol. 2018; 108: 125-131.

Mutai H, Watabe T, Kosaki K. et al. Mitochondrial mutations in maternally inherited hearing loss. BMC Med Genet. 2017; 18: 32.

Zhu Y, Zong L, Mei L, et al. Connexin26 gap junction mediates miRNA intercellular genetic communication in the cochlea and is required for inner ear development. Scientific Reports 5, 2015; Article number:15647. DOi: 10.1038/srep15647

Meng M, Huo R, Han MY, et al. Detection of common deaf- ness mutation by maternal plasma cell-free DNA. European Review for Medical and Pharmacological Sciences 2014; 18(10): 1544-48.